Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA)

Rheumatol Int. 2011 Dec;31(12):1661-4. doi: 10.1007/s00296-010-1787-5. Epub 2011 Jan 15.

Abstract

The exact elucidation of skeletal and cartilagineous involvement in neonatal-onset multisystem inflammatory disease (NOMID) is still poorly known, and there are few data providing the long-term response to treatment with the available interleukin-1 inhibitors. We present here a 13-year-old boy with NOMID treated with anakinra and low-dose methylprednisolone since he was 7 years old for an overall period of 6 years. Every clinical manifestation was highly responsive to interleukin-1 blockade, with the exception of his bone abnormalities. At the comparison of radiography and magnetic resonance imaging of his knees made respectively at 7 and 13 years, we noticed a bone erosion on the posterior surface of the patella combined with the progression of distal femoral overgrowth and endosteal thinning of both meta-epiphyses. This report must encourage clinicians in a precocious institution of interleukin-1 antagonists to thwart the occurrence of irreversible bone changes.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antirheumatic Agents / therapeutic use*
  • Bone Resorption / diagnostic imaging
  • Bone Resorption / drug therapy*
  • Bone Resorption / prevention & control
  • Carrier Proteins / genetics
  • Cryopyrin-Associated Periodic Syndromes / diagnosis
  • Cryopyrin-Associated Periodic Syndromes / drug therapy*
  • Cryopyrin-Associated Periodic Syndromes / genetics
  • Drug Therapy, Combination
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Interleukin-1 / antagonists & inhibitors
  • Knee / diagnostic imaging
  • Magnetic Resonance Imaging
  • Male
  • Methylprednisolone / therapeutic use
  • Mutation, Missense
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Radiography
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Carrier Proteins
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
  • Methylprednisolone